Armistice Capital LLC Increases Stock Holdings in NeuroPace, Inc. $NPCE

Key Points

• Armistice Capital LLC significantly increased its stake in NeuroPace, Inc. by 94.7%, acquiring an additional 561,000 shares and now holding over 1.15 million shares valued at approximately $14.18 million.
• Several research firms have varied opinions on NeuroPace's stock, with a consensus rating of "Moderate Buy" and an average price target of $16.60, despite recent modifications by firms like Wells Fargo and Zacks Research.
• NeuroPace reported a net loss with an EPS of ($0.26) that fell short of estimates, while their revenue of $23.52 million surpassed expectations, indicating mixed performance.

Armistice Capital LLC boosted its position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 94.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,153,614 shares of the company's stock after buying an additional 561,000 shares during the period. Armistice Capital LLC owned approximately 3.52% of NeuroPace worth $14,178,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of NeuroPace in the 4th quarter valued at approximately $29,000. GAMMA Investing LLC bought a new position in shares of NeuroPace in the 1st quarter valued at $53,000. Wells Fargo & Company MN lifted its stake in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after acquiring an additional 2,279 shares during the last quarter. MetLife Investment Management LLC bought a new position in shares of NeuroPace in the 4th quarter valued at $103,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of NeuroPace in the 4th quarter valued at $112,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Stock Up 0.2%

Shares of NASDAQ NPCE traded up $0.02 during trading on Friday, hitting $9.63. The stock had a trading volume of 85,660 shares, compared to its average volume of 269,950. NeuroPace, Inc. has a 12 month low of $5.45 and a 12 month high of $18.98. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. The company has a market capitalization of $318.47 million, a PE ratio of -11.51 and a beta of 1.90. The firm has a fifty day moving average of $9.28 and a two-hundred day moving average of $11.32.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%.The firm had revenue of $23.52 million during the quarter, compared to the consensus estimate of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NPCE has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 14th. HC Wainwright initiated coverage on shares of NeuroPace in a research report on Wednesday, May 28th. They set a "buy" rating and a $18.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $17.00 target price on shares of NeuroPace in a research report on Wednesday, May 14th. Wells Fargo & Company cut their target price on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Finally, Zacks Research lowered shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.60.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.